Cedric Graebin
A
In response to Peter Smit.
"if you build it, they will come", newsletter edition. I liked it.
03:36 AM - May 03, 2023
1
2
Cedric Graebin
A
In response to TinaG.
For one, we already use genomic information in a large scale in drug development (e.g.: targeting receptor isoforms, designing drugs for a mutated receptor that is resistant to current drugs, etc.). For a personalized medicine, the barrier is the massive cost of developing a drug/number of patients
03:35 AM - Apr 04, 2023
0
0
Cedric Graebin
A
In response to Creative AF (She/Her).
You know, for the past 20 years there has been some people trying to change this:
- the Doctors Without Borders MSF Access campaign
- Drugs for Neglected Diseases initiative (DNDi)
- Medicines for Malaria Venture (MMV)

(disclaimer: I work on a MMV-funded project, so I might be biased)
11:44 AM - Mar 31, 2023
1
2
Cedric Graebin
A
In response to Warren Oakley.
I would say (my knowledge on NPs is small, I must admit) that the challenge for NPs in therapy would be 1) how to make the NPs reach the affected area of the body and 2) how to safely activate them and make them target only (or mostly) the affected cells
11:40 AM - Mar 31, 2023
0
1
Cedric Graebin
A
In response to Kathleen Rupnow.
Hi Kathleen! - There are some new drugs on clinical trials for the disease trying to be more than symptom alleviating agents - https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd229002
11:36 AM - Mar 31, 2023
1
0
Cedric Graebin
A
In response to Ellen Leigh.
Normally the INN or generic name is given when the drug enters Phase II clinical trials, around 2-5 years in average before market authorization. The proprietary name (e.g.: Tylenol (r), whose generic name is acetaminophen) comes later, but before Phase III ends (prior to market authorization)
11:26 AM - Mar 31, 2023
0
1
Cedric Graebin
A
In response to Tina Tague.
1) I am so sorry. I have someone close to me who has it and it is a drag.
2) It doesn't seem to be some that would be a breakthrough on the horizon, mostly improvements on current therapies - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036118/
3) It seems that some cognitive therapies and acupu
11:24 AM - Mar 31, 2023
1
1
Cedric Graebin
A
In response to April Sparkles.
Hi April!
Today I learned some new info! Yes, there is a very good correlation between having EBV and MS (ca. 95% of MS patients test positive for EBV) and also there is mounting evidence for a cause-effect going on (https://tinyurl.com/nhh4e59s). As for vaccines, there are 3 on Phase I trials.
09:24 AM - Mar 31, 2023
4
18
Cedric Graebin
A
In response to Ed Lynch.
06:15 AM - Mar 31, 2023
0
3
loading...
{{ notificationModalContent }} {{ promptModalMessage }}